• Greg Barclay, Michael Barbato, Rachel Yerbury, Laura Harnish, and Nilda Miranda.
• Palliative Care Services, Illawarra Shoalhaven Local Health District, Wollongong, NSW, Australia.
• Palliat Med. 2024 Jul 1; 38 (7): 755758755-758.

BackgroundTracheostomy ventilation in motor neurone disease is an uncommon life-sustaining treatment. Best practice is having a plan for ventilation withdrawal, but the literature to guide practice is limited. Case reports have documented standard doses of opioids and benzodiazepines used for sedation in such cases.CaseA 49-year-old man was diagnosed with motor neurone disease in 2016. He commenced tracheostomy ventilation in 2018. In 2022 and 2023, planning was undertaken, at the patient's request, for withdrawal of tracheostomy ventilation at home, when he was no longer able to communicate with technology.Case PlanningPlanning included Bispectral Index monitoring prior to cessation of ventilation, ensuring this only occurred when deep sedation was achieved. After ventilation withdrawal in 2023, a retrospective review of medications given and his level of sedation on monitoring was undertaken, with family consent.OutcomeVentilation withdrawal was initiated after deep sedation was achieved, 6 h after commencing subcutaneous infusions of morphine, midazolam, clonazepam and phenobarbital.LessonsDoses required to achieve acceptable sedation exceeded literature reports. Achieving deep sedation was a longer than expected process.ConclusionMore research using an objective measure of sedation is required, as clinical assessment of sedation in this context is compromised.

19 keywords...

hide…